Home・Lista de Ações・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Fechado

4.13 -2.82

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.12

Máximo

4.38

Indicadores-chave
By Trading Economics
Rendimento	-42M -78M
EPS	-0.59
Funcionários	106
EBITDA	-42M -77M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+105.83% upside

Dividendos
By Acuity
Próximos Ganhos	6 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-34M 297M
Abertura anterior	6.95
Fecho anterior	4.13

Zentalis Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de ago. de 2026, 23:56 UTC

News

Molson Coors Beverage Co shares advanced in after-market hours to $43.20, following Q2 revenues of $3.10 billion that met analyst expectations.

13 de ago. de 2026, 23:56 UTC

GitLab Inc. shares are trading lower in after-market hours, despite an earlier rebound from session lows. No specific news was identified.

13 de ago. de 2026, 23:56 UTC

Pegasystems Inc. shares are lower in after-market trading, with no specific news identified. The broader market reacts to rising initial jobless claims.

13 de ago. de 2026, 23:56 UTC

Zebra Technologies shares are trading higher in after-market hours, maintaining strength above its 20-day moving average and near the upper end of its one-month range.

13 de ago. de 2026, 23:56 UTC

Correlated Moves

T Rowe Price Group Inc shares are lower in after-market trading, extending a trend of declines over the past three sessions amid broader market weakness.

13 de ago. de 2026, 23:56 UTC

iShares TIPS Bond ETF traded roughly flat during after-market hours. The asset remains near the lower end of its one-month trading range.

13 de ago. de 2026, 23:56 UTC

Cherry Hill Mortgage Investment Corp is trading lower in after-market hours, declining from earlier gains despite remaining above its 20-day moving average.

13 de ago. de 2026, 23:56 UTC

Toast Inc shares are lower in after-market trading. No specific company news was identified to explain this price movement.

13 de ago. de 2026, 23:56 UTC

Correlated Moves

Skyworks Solutions Inc shares declined in after-market trading, influenced by broader market movements and rising initial jobless claims indicating potential labor market softness.

13 de ago. de 2026, 23:56 UTC

Shares of Camtek Ltd are trading higher in after-market hours, remaining above their 20-day moving average despite routine performance during the regular session.

13 de ago. de 2026, 23:56 UTC

NetApp Inc. shares are higher in after-market trading, remaining above their 20-day moving average amid broader market dynamics and rising initial jobless claims.

13 de ago. de 2026, 23:56 UTC

Correlated Moves

TPG Inc shares declined in after-market trading, settling lower after earlier gains. The drop aligns with a slight decrease in the Russell 2000 Index.

13 de ago. de 2026, 23:56 UTC

News

Event

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.

13 de ago. de 2026, 23:56 UTC

Correlated Moves

Macro News

ETF Constituents

iShares MSCI South Korea ETF gains in after-market trading, reflecting KOSPI's surge amid positive sentiment around interest rates and U.S. stock performance.

13 de ago. de 2026, 23:52 UTC

Kura Oncology Inc is trading higher in after-market hours, reflecting broader market optimism following recent economic data and a stable producer price index.

13 de ago. de 2026, 23:51 UTC

Tyler Technologies Inc shares are higher in after-market trading, reflecting strong performance since Thursday's close, despite no specific news identified to explain the movement.

13 de ago. de 2026, 23:51 UTC

Clean Energy Fuels Corp shares are lower in after-market hours, reversing earlier gains amid broader market sentiment influenced by recent economic data.

13 de ago. de 2026, 23:51 UTC

Gladstone Land Corp. shares rose in after-market trading, recovering from earlier losses amid broader market optimism following unchanged producer price index data.

13 de ago. de 2026, 23:51 UTC

L3Harris Technologies Inc. shares are higher in after-hours trading, reflecting positive market sentiment amid decreased expectations for a Federal Reserve interest rate hike.

13 de ago. de 2026, 23:51 UTC

StoneX Group Inc shares are lower in after-market hours, with no specific news identified. The asset remains near the lower end of its one-month trading range.

13 de ago. de 2026, 23:51 UTC

Asia equity markets show mixed performance as Japan's Nikkei rises on tech optimism and potential rate hikes, while China's Shanghai Composite dips amid geopolitical tensions and falling oil prices; U.S. jobless claims exceed expectations, softening inflation outlook.

13 de ago. de 2026, 23:51 UTC

Global equity markets rise, led by U.S. mega-caps, while mixed economic signals emerge from jobless claims and inflation data.

13 de ago. de 2026, 23:51 UTC

Mixed trading in European equities as UK GDP growth exceeds expectations while industrial production shows weakness amidst fluctuating oil prices and trade balance concerns.

13 de ago. de 2026, 23:51 UTC

U.S. equity indices remain flat as investors weigh mixed economic signals, rising jobless claims, and easing inflation amid geopolitical tensions and falling oil prices.

13 de ago. de 2026, 23:51 UTC

Australia's Westpac Consumer Confidence Report Set for August 18 Amidst Cautious Market Sentiment and Inflation Concerns.

13 de ago. de 2026, 23:51 UTC

Michigan Consumer Sentiment Report Set for August 14, Forecasted at 54.5 Amid Cautious Optimism Following Stable Inflation Data

13 de ago. de 2026, 23:51 UTC

US Business Inventories MoM data for June 2026 set to release on August 14, with a modest increase of 0.1% anticipated amid cautious market sentiment and inflation concerns.

13 de ago. de 2026, 23:51 UTC

Cautious Market Awaits July 2026 Building Permits Data Amid Ongoing Construction Sector Weakness and Rising Costs

13 de ago. de 2026, 23:51 UTC

NIO Inc shares are higher in after-market trading, reflecting broader market trends amid unchanged producer prices and reduced interest rate hike expectations.

13 de ago. de 2026, 23:51 UTC

Digital Realty Trust Inc shares are higher in after-market trading, reflecting broader market optimism following recent economic data and a recovery from earlier lows.

Comparação entre Pares

Variação de preço

Zentalis Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

105.83% parte superior

Previsão para 12 meses

Média 8.83 USD 105.83%

Máximo 11 USD

Mínimo 5 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Zentalis Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

Comprar

Manter

Vender

Com base em 6 analistas que deram avaliações de ações para Zentalis Pharmaceuticals Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.